Bristol Myers Squibb Announces ZENBEXUS (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3 EXCALIBER-RRMM Study (Bristol-Myers Squibb Press Release) - Oct 8, 2026 - "Results showed ZDd demonstrated a statistically significant improvement in the dual-primary endpoint of progression-free survival (PFS), with median PFS of 42 months for ZDd vs. 20 months for daratumumab, bortezomib and dexamethasone (DVd) [HR:0.49, p<0.000001], representing a 51% reduction in the risk of disease progression or death. Median follow-up was 23 months. The safety profile of ZENBEXUS in combination with standard therapies remained consistent with previously reported safety findings from the study...This data will be presented at the 68th Annual Meeting of the American Society of Hematology in New Orleans, L.A. Bristol Myers Squibb thanks the patients and investigators who participated in the EXCALIBER-RRMM clinical trial."
P3 data: top line • Multiple Myeloma
|